FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies
FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.
Pulmonary Hypertension Associated With Increased Risk of Progression in Patients With Myeloproliferative Neoplasms
Pulmonary hypertension significantly increases the risk of disease progression and cardiovascular events in patients with myelofibrosis, emphasizing a need for…
Michigan doctor sentenced in $6.3 million Medicare fraud scheme
A Michigan doctor has been sentenced to four years in prison for a $6.3 million Medicare fraud scheme in which…
Ropeginterferon Alfa 2b Is Well-Tolerated, Efficacious in Treatment of Prefibrotic Myelofibrosis
Ropeginterferon alfa-2b shows promising results in treating pre-primary myelofibrosis, enhancing clinical responses and safety in patients.
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive…
21-Valent Pneumococcal Conjugate Vaccine Exhibits Consistent Safety and Immunogenicity Across Manufacturing Lots
Across 3 different manufacturing lots, V116 (21-valent pneumococcal conjugate vaccine) demonstrated consistent immunogenicity and efficacy against S pneumoniae, which causes…
ASCO 2025: How AI-Powered Tools Are Reshaping Oncology Data Capture and Clinical Decision-Making
Gayathri Namasivayam, PhD, discusses how large language models are being used to extract structured oncology data from unstructured electronic health…
Study Sheds Light on Impact of Vaccination, Infection on Anti-RSV IgG Levels
A recent study reveals high RSV antibody levels in older adults, highlighting the importance of vaccination and natural infection for…
Navigating the Complexities of cGVHD Treatment in Pharmacy Practice
Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists…
FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease
The FDA approves emapalumab-lzsg as the first treatment for macrophage activation syndrome in Still disease, offering a new treatment approach…